Larimar Therapeutics

Pioneering Leap for Friedreich’s Ataxia Treatment: Larimar Therapeutics Announces Encouraging Phase 2 Results for Nomlabofusp

BALA CYNWYD, PA — The clinical-stage biotech firm Larimar Therapeutics has reported promising top-line data from its Phase 2 dose exploration study. The groundbreaking study tested the medication ‘nomlabofusp’ on …

Pioneering Leap for Friedreich’s Ataxia Treatment: Larimar Therapeutics Announces Encouraging Phase 2 Results for Nomlabofusp Read More


NRx Pharmaceuticals

NRx Pharmaceuticals Clinches $5M Milestone Achievement for Breakthrough in Bipolar Depression Treatments

WILMINGTON, DE — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a pivotal player within the healthcare industry, this week announced a significant milestone in their ongoing quest to combat suicidal bipolar depression. …

NRx Pharmaceuticals Clinches $5M Milestone Achievement for Breakthrough in Bipolar Depression Treatments Read More